In this study, we designed Her2.BBz.PD-L1 CAR T cells and CD19.BBz.PD-L1 CAR T cells for the treatment of breast cancer and B-ALL, respectively. The gene discussed is ERBB2; the disease is acute lymphoblastic leukemia.